Eli Lilly plans to transform India's pharmaceutical market with innovative treatments for diabetes and obesity, leveraging AI and global expertise to address the country's health c...
Eli Lilly & Co. plans to introduce Mounjaro, its diabetes and weight-loss medication, in China, India, Brazil, and Mexico, targeting up to 900 million patients. The move comes as d...
Eli Lilly and Co. reported a 45% increase in Q4 2024 revenue to $13.5 billion, with net income up 101% to $4.4 billion. The company anticipates 2025 revenue between $58 billion and...
Eli Lilly and Company forecasts a significant revenue increase to $58-61 billion by 2025, driven by strong sales of its diabetes and obesity treatments, Mounjaro and Zepbound. CEO ...
Eli Lilly and Company is reportedly finalizing a $2.5 billion acquisition of Scorpion Therapeutics, with a $1 billion upfront payment and up to $1.5 billion more based on performan...
